Drug Profile


Alternative Names: AG 120

Latest Information Update: 21 Jun 2017

Price : $50

At a glance

  • Originator Agios Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Isocitrate dehydrogenase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Cholangiocarcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cholangiocarcinoma
  • Phase I/II Acute myeloid leukaemia
  • Phase I Glioma; Myelodysplastic syndromes; Solid tumours

Most Recent Events

  • 15 Jun 2017 Agios Pharmaceuticals plans to initiate the phase III AGILE trial in Acute myeloid leukaemia (First-line therapy, Combination therapy) (PO) (NCT03173248)
  • 03 Jun 2017 Updated adverse events, efficacy and pharmacodynamics data from a phase I trial in Solid tumours presented at the Annual Meeting of American Society of Clinical Oncology (ASCO-2017)
  • 04 May 2017 Agios Pharmaceuticals announces intention to submit NDA to the US FDA for IDH1m positive Acute myeloid leukaemia (Second-line therapy or greater) by the end of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top